Literature DB >> 1915583

Anticonvulsant and sleep-waking influences of riluzole in a rat model of absence epilepsy.

S Romettino1, M Lazdunski, C Gottesmann.   

Abstract

Six WAG/Rij rats, an animal model of human absence epilepsy, were injected intraperitoneally with riluzole. At 4 mg/kg, riluzole decreased the number, mean duration and spike-frequency of the spontaneously occurring discharges for 3 h. Riluzole also increased slow wave sleep at the expense of waking. As riluzole at 3 mg/kg decreased the number and spike-frequency of the discharges without inducing a sedative effect, this compound could be of therapeutic interest in human absence epilepsy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1915583     DOI: 10.1016/0014-2999(91)90503-i

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms.

Authors:  Joyce Besheer; Veronique Lepoutre; Clyde W Hodge
Journal:  Alcohol Clin Exp Res       Date:  2009-08       Impact factor: 3.455

2.  Inhibition of Navβ4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide.

Authors:  Jonathan W Theile; Theodore R Cummins
Journal:  Mol Pharmacol       Date:  2011-07-25       Impact factor: 4.436

Review 3.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

4.  Prax330 reduces persistent and resurgent sodium channel currents and neuronal hyperexcitability of subiculum neurons in a mouse model of SCN8A epileptic encephalopathy.

Authors:  Eric R Wengert; Anusha U Saga; Payal S Panchal; Bryan S Barker; Manoj K Patel
Journal:  Neuropharmacology       Date:  2019-07-03       Impact factor: 5.250

5.  A neuronal two P domain K+ channel stimulated by arachidonic acid and polyunsaturated fatty acids.

Authors:  M Fink; F Lesage; F Duprat; C Heurteaux; R Reyes; M Fosset; M Lazdunski
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

Review 6.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes.

Authors:  Jonathan W Theile; Theodore R Cummins
Journal:  Front Pharmacol       Date:  2011-10-04       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.